Categories: News

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program

HENDERSON, Nev., July 30, 2021 /PRNewswire/ — PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation & Life Sciences Company developing Psilocybin (“Magic Mushroom”) based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.

“Quantum Technology could ultimately change the way that Humans digest supplements, medications and nutrients.”

PsiloThera’s Clinical Focus is the Treatment of Mental Illnesses including: Depression, Anxiety, PTSD, Eating Disorders & Addictions and Cognitive Diseases & Neurological Disorders such as Alzheimer’s, Dementia and Autism.

PsiloThera’s specialized treatment programs will provide care for Vets, 1st Responders & Patients with Treatment Resistant Mental Illnesses.

PsiloThera CEO, John Atanasio states,”PsiloThera is among the first companies focused on developing novel therapeutics by deploying Quantum Technology that can collect and send materials through organic devices.”

“PsiloThera’s strategy is to have its products lead the future of energy-based nutrients and medication delivery systems.”  “Quantum technology may lead to advances that could ultimately change the way that Humans digest supplements, medications and nutrients.”

“Our Quantum Technology Advisors projects that the technology projects to deliver significant improvements in areas  of Pharmaceutical dispensing issues and adverse effects.”

“Quantum Technology may lead to significant reductions in drug development time and costs, giving PsiloThera a possible major competitive advantage if that were to prove true”

The Journal of American Medical Association- “JAMA PSYCHIATRY” reported in a 2020 study that a treatment of Psilocybin “Magic Mushrooms” works much better than usual anti-depressant medications.

PsiloThera’s outstanding battle tested management team will operate the Company’s  vertical business model  which includes; Fungi Grow, Research & Development, Drug Development, Tele-Mental Health Platform and PsiloThera Treatment Centers.

PsiloThera just launched a Crowdfund Campaign @  www.startengine.com/psilothera 

Start Engine’s spokesperson is non-other than Shark Tank’s TV Show Personality, “Mr. Wonderful” Kevin O’Leary.

Source & Contacts: PsiloThera Inc.   john@psilothera.com    sara@startengine.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/psychedelic-healthcare-innovation-psilothera-announces-launch-of-quantum-technology-drug-development-program-301345163.html

SOURCE PsiloThera Inc.

Staff

Recent Posts

Arlington Medical Waste Disposal Company Addresses Rising Needlestick Injuries With Handy Guide

The CDC Reports Approximately 385,000 Needlestick and Sharps-Related Injuries Among U.S. Healthcare Workers AnnuallyARLINGTON, TX…

1 hour ago

poLight ASA receives purchase order for TWedge® wobulator technical samples from a top tier consumer OEM customer

TØNSBERG, Norway, Nov. 21, 2024 /PRNewswire/ -- poLight ASA (OSE: PLT) today announced that the…

4 hours ago

Waud Capital Partners Releases First Annual Responsible Investing Report

CHICAGO, Nov. 21, 2024 /PRNewswire/ -- Waud Capital Partners ("Waud Capital"), a growth-oriented middle-market private equity…

4 hours ago

Rightway Partners with Curai Health to Expand Access to High-Quality, Affordable Virtual Care

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Today, Rightway, a company transforming care navigation and pharmacy…

4 hours ago

Aires Tech Showcases Advanced Technology at UFC Performance Institute with “Next Frontier of UFC Training and Performance” Symposium

Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC…

4 hours ago

Space-Grown Brain Organoids Help Advance New Neurological Treatment

Startup Leverages ISS National Lab to Test Viral Vector That Delivers Gene Therapy KENNEDY SPACE…

4 hours ago